Big Pharma’s bottom line is leaving the world vulnerable to pandemics

  • “The possibility for blockbuster sales motivates large drugmakers; little else moves the needle. The revenue potential for many infectious disease drugs is likely to remain limited, so other serious incentives are required,” Bloomberg Opinion’s Max Ni…
    Read More


  • No comments yet.
  • Add a comment